You are here:

tenofovir disoproxil (Viread)

Advice

following an abbreviated submission:

tenofovir disoproxil (Viread®) is accepted for restricted use within NHS Scotland.

Indication under review:
HIV-1 infection - in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with nucleoside reverse transcriptase inhibitor (NRTI) resistance or toxicities precluding the use of first line agents, from 2 to < 6 years of age, and above 6 years of age for whom a solid dosage form is not appropriate; and, in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults for whom a solid dosage form is not appropriate.

Hepatitis B infection - for the treatment of chronic hepatitis B in adults for whom a solid dosage form is not appropriate with compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis; decompensated liver disease; and, for the treatment of chronic hepatitis B in adolescents 12 to <18 years of age for whom a solid dosage form is not appropriate with compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis.

SMC restriction: in patients <18 years, to be prescribed under the supervision of specialists in paediatric infectious diseases.

SMC has previously accepted tenofovir disoproxil for use in combination with other antiretroviral agents in HIV infected patients over 18 years of age experiencing virological failure.  SMC has previously accepted tenofovir disoproxil for use in the treatment of chronic hepatitis B in adults with compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis and in patients with decompensated liver disease.

Tenofovir disoproxil is listed in the British National Formulary for Children 2012-2013 for the treatment of hepatitis B infection and HIV infection.

Drug Details

Drug Name: tenofovir disoproxil (Viread)
SMC Drug ID: 905/13
Manufacturer: Gilead Sciences Ltd
Indication: HIV-1 infection - in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with nucleoside reverse transcriptase inhibitor (NRTI) resistance or toxicities precluding the use of first line agents, from 2 to < 6 years of age, and above 6 years of age for whom a solid dosage form is not appropriate; and, in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults for whom a solid dosage form is not appropriate.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 9 September 2013

Back